IP Verse

Compositions Of Grapiprant And Methods For Using The Same - EP3113774

The patent EP3113774 was granted to Aratana Therapeutics on Jan 26, 2022. The application was originally filed on Mar 5, 2015 under application number EP15758877A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3113774

ARATANA THERAPEUTICS
Application Number
EP15758877A
Filing Date
Mar 5, 2015
Status
Granted And Under Opposition
Dec 24, 2021
Grant Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

VIRBACOct 25, 2022IPAZADMISSIBLE
KRKASep 21, 2022KUTZENBERGER WOLFF & PARTNERADMISSIBLE

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6710054
DESCRIPTIONUS7141580
DESCRIPTIONUS7479564
DESCRIPTIONUS7960407
DESCRIPTIONWO0232900
DESCRIPTIONWO2006095268
DESCRIPTIONWO2012157288
INTERNATIONAL-SEARCH-REPORTUS2008206309
INTERNATIONAL-SEARCH-REPORTUS2008242713
INTERNATIONAL-SEARCH-REPORTUS2009018158
INTERNATIONAL-SEARCH-REPORTUS2009036495
INTERNATIONAL-SEARCH-REPORTUS2009253756
INTERNATIONAL-SEARCH-REPORTUS2013225609
INTERNATIONAL-SEARCH-REPORTUS6861441
OPPOSITIONUS2002107273
OPPOSITIONUS2003236260
OPPOSITIONUS2009253756
OPPOSITIONUS6710054
OPPOSITIONWO0232422
OPPOSITIONWO2006095268
OPPOSITIONWO2011102149
OPPOSITIONWO2014148053
SEARCHWO0232422
SEARCHWO2006095268
SEARCHWO9850033

Non-Patent Literature (NPL) Citations (50) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- A. DUGDALE et al., "Veterinary Anaesthesia: Principles to Practice", School of Veterinary Science, (20100000), pages 19 - 24, XP055972020
OPPOSITION- Anonymous, "2014 ACVIM Forum Research Abstracts Program", J Vet Intern Med, (20140428), vol. 28, no. 3, pages 976 - 1134, XP055971941
OPPOSITION- Anonymous, "2014 ACVIM Forum Research Abstracts Program", J Vet Intern Med, (20140428), vol. 28, pages 976 - 1134, XP055971941
OPPOSITION- Anonymous, "History of Changes for Study: NCT00392080 A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers", ClinicalTrials.gov, (20080318), pages 1 - 4, XP055972027
OPPOSITION- Anonymous, "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO Drug Information, (20130000), vol. 27, no. 4, pages 399 - 458, XP055971996
OPPOSITION- Anonymous, "RaQualia innovators for life", RaQualia, (20120000), pages 1 - 47, URL: http://www.raqualia.co.jp, XP055972031
OPPOSITION- B. D. X. LASCELLES, "Guidelines for Safe and Effective Use of NSAIDs in Dogs", Veterinary Therapeutics, (20050000), vol. 6, no. 3, pages 237 - 251, XP055972015
OPPOSITION- C. K. CASSEL et al., "Geriatric Medicine: An Evidence-Based Approach Fourth Edition", Springer, (20030000), pages 71 - 75, XP055971967
OPPOSITION- Cox Sherry, Et Al, "Determination of grapiprant plasma and urine concentrations in horses", Veterinary Anaesthesia and Analgesia, (20200101), vol. 47, pages 705 - 709, XP055980021
OPPOSITION- Cunningham Fiona, Jonathan Elliott, Peter Lees, " 3 Discussion and Conclusions", Comparative and Veterinary Pharmacology, Springer, (20100101), pages 149 - 152, ISBN 978-3-642-10323-0, XP093121861
OPPOSITION- David Salsburg, "Dose finding based on preclinical studies", David Salsburg, N. TING et al., Dose Finding in Drug Development, Springer, (20060000), pages 18 - 29, XP055972100
OPPOSITION- D.C. PLUMB, "Veterinary Drug Handbook 7th edition", Veterinary Drug Handbook 7th edition, Pharma Ve t Inc., (20110000), pages 2929 - 2936, XP055972118
OPPOSITION- D. M. BOOTHE, "Veterinary Compounding in Small Animals: A Clinical Pharmacologist's Perspective", Vet Clin Small Anim, (20060000), vol. 36, pages 1129 - 1173, XP055972033
OPPOSITION- G.E. HARDEE et al., "Preclinical Studies", Development and Formulation of Veterinary Dosage Forms second edition, revised and expanded, (19980000), pages 474 - 477, XP055972107
OPPOSITION- "Grapiprant", Papich Mark G, Papich Handbook of Veterinary Drugs, Elsevier, (20200330), pages 418 - 420, ISBN 978-0-323-70957-6, XP055980030
OPPOSITION- J. K. ARONSON, "Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs", Elsevier B. V., (20100000), pages 237 - 239, XP055971978
OPPOSITION- J. K. H. MA et al., "Chapter 10", Basic Physical Pharmacy, (20130000), pages 248 - 252, XP055972138
OPPOSITION- J. ZHENG, "Importance of excipient absorbance background", Formulation and analytical development for low-dose oral drug products, John Wiley & Sons, Inc., (20090000), pages 331 - 333, XP055972133
OPPOSITION- L. RAUSCH-DERRA et al., "Safety of the EP4 Receptor Antagonist, GRAPIPRANT, Administered Daily to Beagle Dogs for 9 Months at 1, 6 and 50 mg/kg", Aratana Therapeutics, Inc., (20140600), pages 1 - 2, XP055971914
OPPOSITION- M. G. PAPICH, "An Update on Nonsteroidal Anti - Inflammatory Drugs (NSAIDs) in Small Animals", Vet Clin Small Anim, (20080000), vol. 38, pages 1243 - 1266, XP055972017
OPPOSITION- M. KAHN et al., "The Merck/Merial Manual for Pet Health", Merck & Co., Inc., (20070000), page 1140, XP055972023
OPPOSITION- Raafat Fahmy, "13 Formulation and Design of Veterinary Tablets", Raafat Fahmy, L. L. AUGSBURGER et al., Pharmaceutical Dosage Forms: Tablets third edition volume 2: Rational Design and Formulation, informa healthcare, (20080000), pages 383 - 431, XP055256116
OPPOSITION- Rausch-Derra L., Et Al., "Safety of the EP4 Receptor Antagonist, GRAPIPRANT, Administered Daily to Beagle Dogs for 9 Months at 1, 6 and 50 mg/kg", Aratana Therapeutics, Inc., (20140601), pages 1 - 2, Aratana Therapeutics, Inc., (20221017), XP055971914
OPPOSITION- R.C. GUPTA et al., "Testing methods for animal drugs", Veterinary Toxicology, Basic and Clinical Principles, Elsevier, (20120000), pages 119 - 120, XP055972115
OPPOSITION- R. C. GUPTA, "OTC Drugs - Analgesics", Veterinary Toxicology: Basic and Clinical Principals, ELSEVIER, (20070000), pages 368 - 373, XP055972122
OPPOSITION- R. SCHMIDT, "Dose-Finding Studies in Clinical Drug Development", Eur J Clin Pharmacol, (19880000), vol. 34, pages 15 - 19, XP055350888
OPPOSITION- R. S. SINATRA et al., "Chapter 12: A stepwise approach to pain management", The Essence of Analgesia and Analgesics, Cambridge University Press, (20110000), pages 66 - 70, XP055971991
OPPOSITION- S. A. KHAN et al., "Toxicology of Frequently Encountered Nonsteroidal Anti-Inflam- matory Drugs in Dogs and Cats", Vet Clin Small Anim, (20120000), vol. 42, pages 289 - 306, XP055972012
OPPOSITION- Sartini Irene, Et Al, "Grapiprant : A Snapshot of the current knowledge", Journal of Veterinary Pharmacology and Therapeutics, (20210531), pages 1 - 10, XP055980025
OPPOSITION- S. F. CROWLEY et al., "An attractive but currently underserved market - Companion Animal Market", Craig-Hallum, (20130722), pages 1 - 17, XP055972007
OPPOSITION- T. VAUGHAN-SCOTT et al., "The pathophysiology and medical management of ca- nine osteoarthritis", Tydskr.S.Afr.vet.Ver., (19970000), vol. 68, no. 1, pages 21 - 25, XP000853896
OPPOSITION- Vich Steering Committee, "Guidance for Industry Target Animal Safety for Veterinary Pharmaceutical Products VICH GL43", U. S. Department of Health and Human Services Food and Drug Administration Center for Veterinary Medicine, (20090000), vol. 185, pages 1 - 19, XP055972111
OPPOSITION- Xiaoming Chen, "Challenges and new technologies of oral controlled release", Xiaoming Chen, H. WEN et al., Oral Controlled Release Formulation Design and Drug Delivery, John Wiley & Sons, Incorporated, (20100000), pages 257 - 258, XP055576747
OPPOSITION- HEATHER K. KNYCH et al., "Detection and pharmacokinetics of grapiprant following oral administration to exercised Thoroughbred horses", Drug Test Anal, (20180325), vol. 10, doi:10.1002/dta.2378, pages 1237 - 1243, XP055919467
OPPOSITION- V. KONYA et al., "E-type prostanoid receptor 4 ( EP 4) in disease and therapy", Pharmacology & Therapeutics, (20130000), vol. 138, doi:10.1016/j.pharmthera.2013.03.006, pages 485 - 502, XP029177919
OPPOSITION- Castleberry, T.A. Lu, B. Smock, S.L. Owen, T.A., "Molecular cloning and functional characterization of the canine prostaglandin E"2 receptor EP4 subtype", PROSTAGLANDINS, US , (20010701), vol. 65, no. 4, doi:10.1016/S0090-6980(01)00129-0, ISSN 0090-6980, pages 167 - 187, XP004247032
OPPOSITION- G. SINHA, "Companion therapeutics", Nature Biotechnology, (20140100), vol. 6, no. 3, pages 12 - 14, XP037923854
OPPOSITION- Sinha Gunjan, "Companion therapeutics", Nature Biotechnology, New York, (20140101), vol. 32, no. 1, doi:10.1038/nbt.2793, ISSN 1087-0156, pages 12 - 14, XP037923854
OPPOSITION- KA Maubach et al, "BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache", British journal of pharmacology, UK , (20090121), vol. 156, no. 2, doi:10.1111/j.1476-5381.2009.00027.x, ISSN 0007-1188, pages 316 - 327, XP071110724
OPPOSITION- V. SHARMA et al., "To scale or not to scale: the principles of dose extrapolation", British Journal of Pharmacology, (20090000), vol. 157, doi:10.1111/j.1476-5381.2009.00267.x, pages 907 - 921, XP071055983
OPPOSITION- Rl Jones, Ma Giembycz, Df Woodward, "Prostanoid receptor antagonists: development strategies and therapeutic applications", British journal of pharmacology, UK , (20090901), vol. 158, no. 1, doi:10.1111/j.1476-5381.2009.00317.x, ISSN 0007-1188, pages 104 - 145, XP055742551
OPPOSITION- A. NAGAHISA et al., "Pharmacology of grapiprant, a novel EP 4 antagonist: receptor binding, efficacy in a rodent postoperative pain model, and a dose estimation for controlling pain in dogs", J. vet. Pharmacol. Therap., (20160906), vol. 40, doi:10.1111/jvp.12349, pages 285 - 292, XP055698711
OPPOSITION- Kazunari Nakao; Et Al, "CJ-023,423, a Novel, Potent and Selective Prostaglandin EP 4 Receptor Antagonist with Antihyperalgesic Properties", JPET, (20070000), vol. 322, pages 686 - 694, XP055358062
OPPOSITION- Kazunari Nakao, Et Al, "CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4 Receptor Antagonist with Antihyperalgesic Properties", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (20070101), vol. 322, no. 2, doi:10.1124/jpet.107.122010, pages 686 - 694, XP055358062
OPPOSITION- D. F. WOODWARD, "International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress", Pharmacol Rev, (20110000), vol. 63, doi:10.1124/pr.110.003517, pages 471 - 538, XP002699352
OPPOSITION- A. MURASE et al., "Characterization of Binding Affinity of CJ-023,423 for Human Prostanoid EP 4 Receptor", Pharmacology, (20080000), vol. 82, doi:10.1159/000125674, pages 10 - 14, XP002695038
OPPOSITION- T. OKUMURA et al., "Effects of the selective EP 4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis", JPP, (20080000), vol. 60, doi:10.1211/jpp.60.6.0007, pages 723 - 730, XP002712071
OPPOSITION- Lesley C. Rausch-Derra et al, "Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs", American Journal of Veterinary Research, US , (20151001), vol. 76, no. 10, doi:10.2460/ajvr.76.10.853, ISSN 0002-9645, pages 853 - 859, XP055405274
OPPOSITION- Borriello Manuela, Stasi Luigi Piero, "Prostaglandin EP 4 antagonists", Pharmaceutical Patent Analyst, (20130000), vol. 2, no. 3, pages 387 - 397, XP055972002
SEARCH- KAZUNARI NAKAO ET AL, "CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4 Receptor Antagonist with Antihyperalgesic Properties", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (20070101), vol. 322, no. 2, pages 686 - 694, XP055358062 [X] 1,3,9 * page 687, column 1, paragraph 3 * * page 691, column 1, paragraph 2 * [Y] 1-14

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents